Skip to main content
Top
Published in: Clinical and Translational Oncology 11/2017

01-11-2017 | Research Article

The spine instability neoplastic score (SINS) in the assessment of response to radiotherapy for bone metastases

Authors: E. Gallizia, G. Apicella, T. Cena, M. Di Genesio Pagliuca, L. Deantonio, M. Krengli

Published in: Clinical and Translational Oncology | Issue 11/2017

Login to get access

Abstract

Background

Vertebral metastases are often causing pain and spine instability. Radiotherapy is of significant benefit for painful spine metastases but the response can be very variable. The spine instability neoplastic score (SINS) is a recent classification system for diagnosis of spinal instability caused by vertebral metastases. We analysed the degree of pain relief, the need of drug therapy and the imaging features and the SINS before and after radiotherapy. In particular, we investigated the possible correlation of spine instability defined by pre-treatment SINS with pretreatment pain and with response to radiotherapy.

Material/methods

This study included 121 patients with spine metastases treated with palliative 3D conformal radiotherapy. Pain “at rest” and “breakthrough pain”, need for drug therapy in terms of “anti-inflammatory”, “weak opioid”, “strong opioid”, imaging studies and SINS were assessed before and after radiotherapy. Statistical analysis was performed by the correlation coefficient of Spearman and Kruskal–Wallis test.

Results

Pain relief after radiotherapy was observed in 50.4 and 57.8% of patients in terms of pain at rest and breakthrough pain, respectively. The correlation between pain before radiotherapy and SINS was not statistically significant for both pain at rest (p = 0.4) and breakthrough pain (p = 0.49). The correlation between pain response after radiotherapy and SINS was statistically significant for both pain at rest (p = 0.007) and breakthrough pain (p = 0.047).

Discussion/conclusion

The degree of instability, classified according to SINS, resulted to be predictive factor for pain response after radiotherapy. SINS might become a valid tool to identify those patients who can benefit the most from radiotherapy.
Literature
1.
go back to reference Grávalos C, Rodríguez C, Sabino A, Seguí MÁ, Virizuela JA, Carmona A, et al. SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clin Transl Oncol. 2016;18:1243–53.CrossRefPubMedPubMedCentral Grávalos C, Rodríguez C, Sabino A, Seguí MÁ, Virizuela JA, Carmona A, et al. SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clin Transl Oncol. 2016;18:1243–53.CrossRefPubMedPubMedCentral
2.
go back to reference Jackson SW, Wong R, Johnston M, Bezjak A, Welan T. Meta-analysis of dose–fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55:594–605.CrossRef Jackson SW, Wong R, Johnston M, Bezjak A, Welan T. Meta-analysis of dose–fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55:594–605.CrossRef
3.
go back to reference Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease. An evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine. 2010;35:E1221–9.CrossRefPubMed Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease. An evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine. 2010;35:E1221–9.CrossRefPubMed
4.
go back to reference Fourney DR, Frangou EM, Ryken TC, DiPaola CP, Shaffrey CI, Berven SH, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the Spine Oncology Study Group. J Clin Oncol. 2011;29:3072–7.CrossRefPubMed Fourney DR, Frangou EM, Ryken TC, DiPaola CP, Shaffrey CI, Berven SH, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the Spine Oncology Study Group. J Clin Oncol. 2011;29:3072–7.CrossRefPubMed
5.
go back to reference Campos M, Urrutia J, Zamora T, Roman J, Canessa V, Borghero Y, et al. The spine instability neoplastic score: an independent reliability and reproducibility analysis. Spine J. 2014;14:1466–9.CrossRefPubMed Campos M, Urrutia J, Zamora T, Roman J, Canessa V, Borghero Y, et al. The spine instability neoplastic score: an independent reliability and reproducibility analysis. Spine J. 2014;14:1466–9.CrossRefPubMed
6.
go back to reference Teixeira WGJ, De Mesquita Coutinho PR, Delboni Marchese L, Narazaki DK, Fogaca Cristante A, Teixeira MJ, et al. Interobserver agreement for the spine instability neoplastic score varies according to the experience of the evaluator. Clinics. 2013;68:213–7.CrossRefPubMedPubMedCentral Teixeira WGJ, De Mesquita Coutinho PR, Delboni Marchese L, Narazaki DK, Fogaca Cristante A, Teixeira MJ, et al. Interobserver agreement for the spine instability neoplastic score varies according to the experience of the evaluator. Clinics. 2013;68:213–7.CrossRefPubMedPubMedCentral
7.
go back to reference Fisher CG, Schouten R, Versteeg AL, Boriani S, Pal Varga P, Rhines LD, et al. Reliability of the Spinal Instability Neoplastic Score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases. Radiat Oncol. 2014;9:69.CrossRefPubMedPubMedCentral Fisher CG, Schouten R, Versteeg AL, Boriani S, Pal Varga P, Rhines LD, et al. Reliability of the Spinal Instability Neoplastic Score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases. Radiat Oncol. 2014;9:69.CrossRefPubMedPubMedCentral
8.
go back to reference Gaze MN, Kelly CG, Kerr GR, Cull A, Cowie VJ, Gregor A, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomized trial of two fractionation schedules. Radiother Oncol. 1997;45:109–16.CrossRefPubMed Gaze MN, Kelly CG, Kerr GR, Cull A, Cowie VJ, Gregor A, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomized trial of two fractionation schedules. Radiother Oncol. 1997;45:109–16.CrossRefPubMed
9.
go back to reference Zeng L, Chow E, Bedard G, Zhang L, Fairchild A, Vassiliou V, et al. Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22. Int J Radiat Oncol Biol Phys. 2002;84:337–42.CrossRef Zeng L, Chow E, Bedard G, Zhang L, Fairchild A, Vassiliou V, et al. Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22. Int J Radiat Oncol Biol Phys. 2002;84:337–42.CrossRef
10.
go back to reference Zeng L, Chow E, Zhang L, Culleton S, Holden L, Jon F, et al. Comparison of pain response and functional interference outcomes between spinal and non-spinal bone metastases treated with palliative radiotherapy. Support Care Cancer. 2012;20:633–9.CrossRefPubMed Zeng L, Chow E, Zhang L, Culleton S, Holden L, Jon F, et al. Comparison of pain response and functional interference outcomes between spinal and non-spinal bone metastases treated with palliative radiotherapy. Support Care Cancer. 2012;20:633–9.CrossRefPubMed
11.
go back to reference Wu JS, Monk G, Clark T, Robinson J, Eigl BJ, Hagen N. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol). 2006;18:539–44.CrossRef Wu JS, Monk G, Clark T, Robinson J, Eigl BJ, Hagen N. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol). 2006;18:539–44.CrossRef
12.
go back to reference Mc Donald R, Chow E, Rowbottom L, Bedard G, Lam H, Wong E, et al. Quality of life after palliative radiotherapy in bone metastases: a literature review. J Bone Oncol. 2015;4:24–31.CrossRef Mc Donald R, Chow E, Rowbottom L, Bedard G, Lam H, Wong E, et al. Quality of life after palliative radiotherapy in bone metastases: a literature review. J Bone Oncol. 2015;4:24–31.CrossRef
13.
go back to reference Nomiya T, Teruyama K, Wada H, Nemoto K. Time course of pain relief in patients treated with radiotherapy for cancer pain: prospective study. Clin J Pain. 2010;26:38–42.CrossRefPubMed Nomiya T, Teruyama K, Wada H, Nemoto K. Time course of pain relief in patients treated with radiotherapy for cancer pain: prospective study. Clin J Pain. 2010;26:38–42.CrossRefPubMed
14.
go back to reference Schlampp I, Rieken S, Habermehl D, Bruckner T, Forster R, Debus J, et al. Stability of spinal bone metastases in breast cancer after radiotherapy. A retrospective analysis of 157 cases. Strahlenther Onkol. 2014;190:792–7.CrossRefPubMedPubMedCentral Schlampp I, Rieken S, Habermehl D, Bruckner T, Forster R, Debus J, et al. Stability of spinal bone metastases in breast cancer after radiotherapy. A retrospective analysis of 157 cases. Strahlenther Onkol. 2014;190:792–7.CrossRefPubMedPubMedCentral
15.
go back to reference Rief H, Heinhold M, Bruckner T, Schlampp I, Forster R, Welzel T, et al. Quality of life, fatigue and local response of patients with unstable spinal bone metastases under radiation therapy - a prospective trial. Radiat Oncol. 2014;9:133.CrossRefPubMedPubMedCentral Rief H, Heinhold M, Bruckner T, Schlampp I, Forster R, Welzel T, et al. Quality of life, fatigue and local response of patients with unstable spinal bone metastases under radiation therapy - a prospective trial. Radiat Oncol. 2014;9:133.CrossRefPubMedPubMedCentral
16.
go back to reference Rief H, Bischof M, Bruckner T, Welzel T, Askoxylakis V, Rieken S, et al. The stability of osseous metastases of the spine in lung cancer—a retrospective analysis of 338 cases. Radiat Oncol. 2013;8:200.CrossRefPubMedPubMedCentral Rief H, Bischof M, Bruckner T, Welzel T, Askoxylakis V, Rieken S, et al. The stability of osseous metastases of the spine in lung cancer—a retrospective analysis of 338 cases. Radiat Oncol. 2013;8:200.CrossRefPubMedPubMedCentral
17.
go back to reference Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol. 2012;24:112–24.CrossRef Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol. 2012;24:112–24.CrossRef
18.
go back to reference Goblirsch MJ, Zwolak PP, Clohisy DR. Biology of bone cancer pain. Clin Cancer Res. 2006;12:6231–5.CrossRef Goblirsch MJ, Zwolak PP, Clohisy DR. Biology of bone cancer pain. Clin Cancer Res. 2006;12:6231–5.CrossRef
19.
go back to reference Huisman M, Van Der Velden JM, Van Vulpen M, Van Den Bosch MAAJ, Chow E, Oner FC, et al. Spinal instability as defined by the spinal instability neoplastic score is associated with radiotherapy failure in metastatic spinal disease. Spine J. 2014;14:2835–40.CrossRefPubMed Huisman M, Van Der Velden JM, Van Vulpen M, Van Den Bosch MAAJ, Chow E, Oner FC, et al. Spinal instability as defined by the spinal instability neoplastic score is associated with radiotherapy failure in metastatic spinal disease. Spine J. 2014;14:2835–40.CrossRefPubMed
Metadata
Title
The spine instability neoplastic score (SINS) in the assessment of response to radiotherapy for bone metastases
Authors
E. Gallizia
G. Apicella
T. Cena
M. Di Genesio Pagliuca
L. Deantonio
M. Krengli
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 11/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1705-3

Other articles of this Issue 11/2017

Clinical and Translational Oncology 11/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine